Clinical Trials
16 trialsNCT04505553 2026-01-21
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
Phase 2 Completed
NCT02279433 2025-06-24
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
Nuvation Bio Inc.
Phase 1 Completed
NCT01638533 2025-02-07
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT06570174 2024-08-26
Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients
Yonsei University
Phase NA Completed
NCT03834701 2024-02-13
RAPNEN
Catholic University of the Sacred Heart
Phase NA Completed
NCT05528614 2023-11-08
ReSiPaTNE
University Hospital, Strasbourg, France
Completed
NCT04476082 2023-01-25
NutriGIT
University Medicine Greifswald
Completed
NCT02685631 2021-09-05
RESiN
Vanderbilt-Ingram Cancer Center
Completed
NCT02948946 2021-08-04
Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Completed
NCT02402062 2020-07-27
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT01525550 2019-07-30
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Pfizer
Phase 4 Completed
NCT00869050 2016-07-25
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
Phase 2 Completed
NCT01135849 2015-11-17
B-Receptor Signaling in Cardiomyopathy
Stanford University
Completed
NCT00363051 2013-05-10
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
Novartis
Phase 2 Completed
NCT00990535 2009-10-07
HIDONET
Federico II University
Phase 2 Completed